Alan E. Friedman

Alan E. Friedman

Auto-generated profile, based on publicly available information

Alan E. Friedman

Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260-3000, United States

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1990 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AFAlan E. Friedman
Alan E. Friedman
JCJean Claude Chambron
Jean Claude Chambron
JSJean Pierre Sauvage
Jean Pierre Sauvage
NTNicholas J. Turro
Nicholas J. Turro
JBJacqueline K. Barton
Jacqueline K. Barton

2 April 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RDRashid Deane
Rashid Deane
ISItender Singh
Itender Singh
ASAbhay P. Sagare
Abhay P. Sagare
RBRobert D. Bell
Robert D. Bell
NRNathan T. Ross
Nathan T. Ross
BZBerislav V. Zlokovic
Berislav V. Zlokovic
In Alzheimer disease (AD), amyloid β peptide (Aβ) accumulates in plaques in the brain. Receptor for advanced glycation end products (RAGE) mediates Aβ-induced perturbations in cerebral vessels, neurons, and microglia in AD. Here, we identified a high-affinity RAGE-specific inhibitor (FPS-ZM1) that blocked Aβ binding to the V domain of RAGE and inhibited Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB). In aged APPsw/0 mice overexpressing human Aβ-precursor protein, a transgenic mouse model of AD with established Aβ pathology, FPS-ZM1 inhibited RAGE-mediated influx of circulating Aβ40 and Aβ42 into the brain. In brain, FPS-ZM1 bound exclusively to RAGE, which inhibited β-secretase activity and Aβ production and suppressed microglia activation and the neuroinflammatory response. Blockade of RAGE actions at the BBB and in the brain reduced Aβ40 and Aβ42 levels in brain markedly and normalized cognitive performance and cerebral blood flow responses in aged APPsw/0 mice. Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of Aβ-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.

1 May 2007 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
RBRobert D Bell
Robert D Bell
ASAbhay P Sagare
Abhay P Sagare
AFAlan E Friedman
Alan E Friedman
GBGurrinder S Bedi
Gurrinder S Bedi
DHDavid M Holtzman
David M Holtzman
BZBerislav V Zlokovic
Berislav V Zlokovic
Amyloid β-peptide (Aβ) clearance from the central nervous system (CNS) maintains its low levels in brain. In Alzheimer's disease, Aβ accumulates in brain possibly because of its faulty CNS clearance and a deficient efflux across the blood—brain barrier (BBB). By using human-specific enzyme-linked immunosorbent assays, we measured a rapid 30 mins efflux at the BBB and transport via the interstitial fluid (ISF) bulk flow of human-unlabeled Aβ and of Aβ transport proteins, apolipoprotein E (apoE) and apoJ in mice. We show (i) Aβ40 is cleared rapidly across the BBB via low-density lipoprotein receptor-related protein (LRP)1 at a rate of 0.21 pmol/min g ISF or 6-fold faster than via the ISF flow; (ii) Aβ42 is removed across the BBB at a rate 1.9-fold slower compared with Aβ40; (iii) apoE, lipid-poor isoform 3, is cleared slowly via the ISF flow and across the BBB (0.03–0.04 pmol/min g ISF), and after lipidation its transport at the BBB becomes barely detectable within 30 mins; (iv) apoJ is eliminated rapidly across the BBB (0.16 pmol/ming ISF) via LRP2. Clearance rates of unlabeled and corresponding 125I-labeled Aβ and apolipoproteins were almost identical, but could not be measured at low physiologic levels by mass spectrometry. Amyloid β-peptide 40 binding to apoE3 reduced its efflux rate at the BBB by 5.7-fold, whereas Aβ42 binding to apoJ enhanced Aβ42 BBB clearance rate by 83%. Thus, Aβ, apoE, and apoJ are cleared from brain by different transport pathways, and apoE and apoJ may critically modify Aβ clearance at the BBB.

1 November 1992 in Biochemistry
Verified
Journal Article
Closed access
YJYonchu Jenkins
Yonchu Jenkins
AFAlan E. Friedman
Alan E. Friedman
NTNicholas J. Turro
Nicholas J. Turro
JBJacqueline K. Barton
Jacqueline K. Barton

1 February 2009 in Biomaterials
Verified
Journal Article
Closed access
MEMorton S. Ehrenberg
Morton S. Ehrenberg
AFAlan E. Friedman
Alan E. Friedman
JFJacob N. Finkelstein
Jacob N. Finkelstein
GOGünter Oberdörster
Günter Oberdörster
James McgrathJames Mcgrath
James Mcgrath

12 April 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SCSamuel Caito
Samuel Caito
SRSaravanan Rajendrasozhan
Saravanan Rajendrasozhan
SCSuzanne Cook
Suzanne Cook
SCSangwoon Chung
Sangwoon Chung
HYHongwei Yao
Hongwei Yao
Irfan RahmanIrfan Rahman
Irfan Rahman
Sirtuinl (SIRT1) deacetylase levels are decreased in chronic inflammatory conditions and aging where oxidative stress occurs. We determined the mechanism of SIRT1 redox post‐translational modifications leading to its degradation. Human lung epithelial cells exposed to hydrogen peroxide (150–250 µM), aldehyde‐acrolein (10–30 µM), and cigarette smoke extract (CSE;0.1–1.5%) in the presence of intracellular glutathione‐modulating agents at 1–24 h, and oxidative post‐translational modifications were assayed in cells, as well as in lungs of mice lacking and overexpressing glutaredoxin‐1 (Glrx1), and wild‐type (WT) mice in response to cigarette smoke (CS). CSE and aldehydes dose and time dependently decreased SIRT1 protein levels, with EC 50 of 1% for CSE and 30 µM for acrolein at 6 h, and >80% inhibition at 24 h with CSE, which was regulated by modulation of intracellular thiol status of the cells. CS decreased the lung levels of SIRT1 in WT mice, which was enhanced by deficiency of Glrx1 and prevented by overexpression of Glrx1. Oxidants, aldehydes, and CS induced carbonyl modifications on SIRT1 on cysteine residues concomitant with decreased SIRT1 activity. Proteomics studies revealed alkylation of cysteine residue on SIRT1. Our data suggest that oxidants/aldehydes covalently modify SIRT1, decreasing enzymatic activity and marking the protein for proteasomal degradation, which has implications in inflammatory conditions.—Caito, S., Rajendrasozhan, S., Cook, S., Chung, S., Yao, H., Friedman, A. E., Brookes, P. S., Rahman, I. SIRT1 is a redox‐sensitive deacetylase that is post‐translationally modified by oxidants and carbonyl stress. FASEB J . 24, 3145–3159 (2010). www.fasebj.org